Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
With the continual evolution of new strains of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that are more virulent, transmissible, and able to evade current vaccines, there is an urgent need for effective anti-viral drugs. The SARS-CoV-2 main protease (M pro ) is a leading target for drug design due to its conserved and indispensable role in the viral life cycle. Drugs targeting M pro appear promising but will elicit selection pressure for resistance. To understand resistance potential in M pro , we performed a comprehensive mutational scan of the protease that analyzed the function of all possible single amino acid changes. We developed three separate high throughput assays of M pro function in yeast, based on either the ability of M pro variants to cleave at a defined cut-site or on the toxicity of their expression to yeast. We used deep sequencing to quantify the functional effects of each variant in each screen. The protein fitness landscapes from all three screens were strongly correlated, indicating that they captured the biophysical properties critical to M pro function. The fitness landscapes revealed a non-active site location on the surface that is extremely sensitive to mutation, making it a favorable location to target with inhibitors. In addition, we found a network of critical amino acids that physically bridge the two active sites of the M pro dimer. The clinical variants of M pro were predominantly functional in our screens, indicating that M pro is under strong selection pressure in the human population. Our results provide predictions of mutations that will be readily accessible to M pro evolution and that are likely to contribute to drug resistance. This complete mutational guide of M pro can be used in the design of inhibitors with reduced potential of evolving viral resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 1×
“site enables the design of covalent inhibitors that provide advantages such as increased potency, selectivity, and duration of inhibition (Singh et al., 2011).”
BackgroundDeep mutational scanning: a new style of protein science
Fowler, D. M., & Fields, S. (2014) · Nature Methods · doi:10.1038/nmeth.3027 · Cited by 1,287 · cited 2×
“mutational scanning assesses the consequences of all point mutations in a gene providing a comprehensive picture of the relationship between protein sequence and function (Hietpas et al., 2011; Fowler and Fields, 2014).”
BackgroundSlightly Deleterious Mutant Substitutions in Evolution
OHTA, T. (1973) · Nature · doi:10.1038/246096a0 · Cited by 1,104
Activity-enhancing mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis
Starita, L. M., Pruneda, J. N., Lo, R. S., Fowler, D. M., Kim, H. J., Hiatt, J. B., Shendure, J., Brzovic, P. S., Fields, S., & Klevit, R. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303309110 · Cited by 183
CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation
Singer, J., Gifford, R., Cotten, M., & Robertson, D. (2020) · doi:10.20944/preprints202006.0225.v1 · Cited by 167
Biering, S. B., Van Dis, E., Wehri, E., Yamashiro, L. H., Wrynla, X. H., Dugast-Darzacq, C., Graham, T. G. W., Stroumza, J. R., Golovkine, G. R., Roberts, A. W., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00017 · Cited by 28
Self-citation
Cited by
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Hu, Y., Lewandowski, E. M., Tan, H., Zhang, X., Morgan, R. T., Zhang, X., Jacobs, L. M. C., Butler, S. G., Gongora, M. V., Choy, J., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00538 · Cited by 333
(2023) · doi:10.1101/2023.12.07.570727 · Cited by 207
Recognition and cleavage of human tRNA methyltransferase TRMT1 by the SARS-CoV-2 main protease
D'Oliviera, A., Dai, X., Mottaghinia, S., Olson, S., Geissler, E. P., Etienne, L., Zhang, Y., & Mugridge, J. S. (2025) · eLife · doi:10.7554/elife.91168.3 · Cited by 13
Recognition and cleavage of human tRNA methyltransferase TRMT1 by the SARS-CoV-2 main protease
D'Oliviera, A., Dai, X., Mottaghinia, S., Olson, S., Geissler, E. P., Etienne, L., Zhang, Y., & Mugridge, J. S. (2025) · eLife · doi:10.7554/elife.91168 · Cited by 2
Metadata
- Authors
- Flynn, J. M., Samant, N., Schneider-Nachum, G., Barkan, D. T., Yilmaz, N. K., Schiffer, C. A., Moquin, S. A., Dovala, D., & Bolon, D. N.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2022-06-20
- Volume
- 11
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W4283161447
- Cited by
- 117
- References
- 7
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. https://app.cochat.ai/papers/10.7554/elife.77433
- The paper
- Flynn, J. M., Samant, N., Schneider-Nachum, G., Barkan, D. T., Yilmaz, N. K., Schiffer, C. A., Moquin, S. A., Dovala, D., & Bolon, D. N. (2022). Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. eLife. https://doi.org/10.7554/elife.77433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.